Potential Biological Effects of (-)-Epigallocatechin-3-gallate on the Treatment of Nonalcoholic Fatty Liver Disease.

about

Potential Biological Effects of (-)-Epigallocatechin-3-gallate on the Treatment of Nonalcoholic Fatty Liver Disease.

Item

http://www.wikidata.org/entity/Q50194612

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Potential Biological Effects o ...... alcoholic Fatty Liver Disease.

@en

Potential Biological Effects of

@nl

type

Item

label

Potential Biological Effects o ...... alcoholic Fatty Liver Disease.

@en

Potential Biological Effects of

@nl

prefLabel

Potential Biological Effects o ...... alcoholic Fatty Liver Disease.

@en

Potential Biological Effects of

@nl

P1476

Potential Biological Effects o ...... alcoholic Fatty Liver Disease.

@en

P2093

Cheng Chen

http://www.w3.org/2001/XMLSchema#string

Lin Liu

http://www.w3.org/2001/XMLSchema#string

Qian Liu

http://www.w3.org/2001/XMLSchema#string

Qin Feng

http://www.w3.org/2001/XMLSchema#string

Yi-Yang Hu

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial-NoDerivatives

P2860

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

The Pathogenesis of Nonalcoholic Fatty Liver Disease: Interplay between Diet, Gut Microbiota, and Genetic Background

Autophagy: a new target for nonalcoholic fatty liver disease therapy

Epigallocatechin Gallate: A Review of Its Beneficial Properties to Prevent Metabolic Syndrome

Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea

Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH)

Weight control and prevention of metabolic syndrome by green tea.

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c

Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity

P31

scholarly article

review article

P356

10.1002/MNFR.201700483

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2017-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28799714

http://www.w3.org/2001/XMLSchema#string

P921

Non-alcoholic fatty liver disease

P932

6120134

http://www.w3.org/2001/XMLSchema#string